KLK3 and cancer: As compared with performing prostate biopsies in all men with PSA ≥ 3 ng/mL, the use of Stockholm3 with a cutoff of 0.11 resulted in saving half of biopsy procedures at the cost of delaying diagnosis for a fifth of the significant cancers.